Cognition Therapeutics price target lowered to $8 from $11 at Chardan

Chardan lowered the firm’s price target on Cognition Therapeutics (CGTX) to $8 from $11 and keeps a Buy rating on the shares after the company reported FY24 financial results and provided updates on its programs. Following “promising” data from Phase 2 studies of zervimesine in Alzheimer’s disease and dementia with Lewy bodies, Cognition will request end of Phase 2 meetings with the FDA to align on plans for Phase 3, the analyst noted.